Integra LifeSciences sets sights on acquiring J&J's Codman Neurosurgery business: 7 insights Featured

Written by  Megan Wood | Wednesday, 15 February 2017 21:21
Social sharing

Plainsboro, N.J.-based Integra LifeSciences made a binding offer to acquire Johnson & Johnson's Codman Neurosurgery business, based in Raynham, Mass.

Here are seven insights:


1. Integra LifeSciences' offered a price of $1.05 billion in cash.


2. The Codman Neurosurgery portfolio includes devices for hydrocephalus, neuro-critical care and operative neurosurgery.


3. Integra hopes to combine Codman's neurosurgery portfolio with its tissue ablation, dural repair and cranial stabilization products to offer a comprehensive neurosurgery portfolio.


4. In 2016, the Codman neurosurgery products generated about $370 million in revenue.


5. Integra anticipates the transaction to be accretive to adjusted earnings-per-share by $0.22 at least in the first full year post-closing.


6. While Integra expects the Codman Neurosurgery revenue to see some disruption in the first year after acquisition, the company believes it will increase 3 percent to 6 percent in the longer term.


7. After the information and consultation process with the employees' representatives in other countries concludes, Integra plans to enter into a definitive purchase and sale agreement.


More articles on devices:
FDA grants Medtronic expanded indication for cancer-fighting OsteoCool Ablation System — 7 takeaways
FDA clears Centric Medical's Metatarsal Hemi Implant System — 5 details
3-D printing for medical sector to grow at 11.7% CAGR through 2024: 5 notes

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months